The battle lines have been drawn between Bristol-Myers Squibb Co. and Exelixis Inc. and partner Ipsen after strong data presented at the recent European Society for Medical Oncology congress in Madrid on their respective first-line renal cell carcinoma therapies saw both being touted as potentially practice-changing.
No Clear Winner in BMS, Exelixis/Ipsen First-line Renal Cancer Race
While the CheckMate-214 data on the Opdivo/Yervoy combo made the headlines at ESMO, a closer look at the results show there is plenty of room for Cabometyx to have sizeable market share.
